1,4-Ditert-butyl-2,2-dimethylpiperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1,4-Ditert-butyl-2,2-dimethylpiperazine
• 英文别名: 1,4-ditert-butyl-2,2-dimethylpiperazine
• 化学式: C₁₄H₃₀N₂
• 分子量: 226.4
• InChiKey: IGUBIBJJSFVADV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE
  申请人：GENZYME CORPORATION

  公开号：US20200102324A1

  公开（公告）日：2020-04-02

  Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).

  本文描述了一种化合物，其化学式为（I），以及其药用盐。本文还描述了这些组合物以及在治疗各种疾病和症状的方法中使用这些组合物，特别是克拉贝氏病（KD）和间染色质白质脑病（MLD）。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：PLEXXIKON INC.

  公开号：US20140128390A1

  公开（公告）日：2014-05-08

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

  本文描述了对c-kit蛋白激酶或携带任何突变的突变c-kit蛋白激酶起作用的化合物，以及制备和使用这种化合物治疗与c-kit蛋白激酶和突变c-kit蛋白激酶的异常活性相关的疾病和病状的方法。
• Compounds and methods for kinase modulation, and indications therefor
  申请人：Plexxikon Inc.

  公开号：US10227357B2

  公开（公告）日：2019-03-12

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

  本文描述了对具有任何突变的 c-kit 蛋白激酶或突变 c-kit 蛋白激酶具有活性的化合物，以及制造和使用此类化合物治疗与 c-kit 蛋白激酶和突变 c-kit 蛋白激酶异常活性相关的疾病和病症的方法。
• Quinazoline and indole compounds to treat medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10961252B2

  公开（公告）日：2021-03-30

  Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

  本研究提供了用于制造补体因子 B 抑制剂的化合物、使用方法和工艺。
• Nitrogen-containing heterocyclic compounds as FXR modulators
  申请人：Hepagene Therapeutics (HK) Limited

  公开号：US10919903B2

  公开（公告）日：2021-02-16

  The present technology is directed to compounds, compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

  本技术涉及与调节 FXR 有关的化合物、组合物和方法。特别是，本化合物和组合物可用于治疗 FXR 介导的疾病和病症，包括肝脏疾病、高脂血症、高胆固醇血症、肥胖症、代谢综合征、心血管疾病、胃肠道疾病、动脉粥样硬化和肾脏疾病等。